Researchers have found in a new study that among men with prostate cancer undergoing androgen deprivation therapy, use of oxybutynin 5 mg twice daily significantly reduced the frequency ...

The findings, published in JAMA Network Open, were reported by Cristian Udovicich of the Odette Cancer Centre at Sunnybrook Health Sciences Centre, Toronto, Canada, and colleagues. The investigators ...

Good morning, everybody. My name is Kyahn Williamson, SVP of Investor Relations and Corporate Communications at Telix. And we're very pleased to welcome you today to our investor call and webcast to ...

A meta-analysis explores whether there’s a survival benefit to adding hormone therapy to postoperative radiation for patients with low PSA levels.

Dr. Kevin Kalinsky discusses common side effects associated with the FDA-approved combination of Enhertu and Perjeta for breast cancer. Antibody-drug conjugates (ADCs) are rapidly changing the ...

For patients with prostate cancer, concurrent use of enzalutamide, apalutamide, or abiraterone with DOACs does not increase risks for thrombosis or bleeding.

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of anticoagulants published by Wiley online in CANCER, investigators found ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

A new study led by researchers at The University of Texas MD Anderson Cancer Center found that prostate cancer patients with low testosterone levels may have a higher risk of cancer progressing to a ...